ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1364

Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

Jeyanesh Tambiah1, Sarah Kennedy1, Heli Ghandehari1, Christopher Swearingen1 and Marc C. Hochberg2, 1Samumed, LLC, San Diego, CA, 2University of Maryland School of Medicine, Baltimore, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: clinical trials, DMOAD, Knee, osteoarthritis and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis – Clinical Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved in these cellular processes. SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, is in development for treatment of knee OA as a potential disease-modifying OA drug (DMOAD). A phase 2, multicenter, 52-week, randomized, double-blind, placebo (PBO)-controlled trial of SM04690 was conducted. Safety and efficacy outcomes including the Western Ontario and McMaster Universities Arthritis Index (WOMAC) were evaluated.

Methods: Subjects with ACR-defined knee OA, Kellgren-Lawrence (KL) grades 2-3, received a single 2 mL IA injection of SM04690 (0.03, 0.07 or 0.23 mg) or PBO in the target (most painful) knee. WOMAC was assessed at baseline and 4, 13, 26, 39 and 52 weeks post-injection. WOMAC question A1, (‘how much pain have you had when walking on a flat surface?’), was analyzed as a post-hoc exploratory outcome. Analysis of covariance adjusted for baseline WOMAC A1 score in the intent-to-treat (ITT) population was conducted. Two subgroups identified in the primary analysis (Yazici Y et al., Arthritis Rheumatol 2017) were also explored: 1) subjects with unilateral symptomatic knee OA (pre-specified) and 2) subjects with unilateral symptomatic knee OA without widespread pain or comorbid symptoms (Widespread Pain Index ≤4 and Symptom Severity ≤2 [WP-], post-hoc).

Results: 455 subjects (mean age 60.3 [±8.7] years, BMI 29.9 [±4.6] kg/m2, female 58.9%, KL 3 [64.1%], unilateral symptomatic OA [36.0%]) were enrolled; 402 [88.4%] completed the study. No safety signals were observed.

For WOMAC A1, in the ITT population, no statistically significant differences between treatment groups and PBO were seen, although the 0.07 mg dose demonstrated improvements compared with PBO at all timepoints (Figure). In unilateral symptomatic subjects, 0.07 mg showed significant improvements in WOMAC A1 compared with PBO at Weeks 39 (-1.2, 95% CI [-2.3, -0.0], P=0.043) and 52 (-1.1, 95% CI [-2.0, -0.1], P=0.027).  

In unilateral symptomatic WP- subjects, the 0.07 mg dose showed significant improvements in WOMAC A1 compared with PBO at Weeks 26 (-1.2, 95% CI [-2.1, -0.2], P=0.015), 39 (-1.8, 95% CI [-3.0, -0.6], P=0.004) and 52 (-1.4, 95% CI [-2.5, -0.4], P=0.010).

Conclusion: In this phase 2 study, improvements compared with PBO in WOMAC A1 were seen in clinically relevant unilateral symptomatic and unilateral symptomatic WP- subgroups. The improvements seen in this combined, multi-dimensional outcome of pain and function suggested SM04690 has a potential role in the treatment of signs and symptoms of knee OA.


Disclosure: J. Tambiah, Samumed, LLC, 1, 3; S. Kennedy, Samumed, LLC, 1, 3; H. Ghandehari, Samumed, LLC, 1, 3; C. Swearingen, Samumed, LLC, 1, 3; M. C. Hochberg, Bioberica, 5,EMD Serono, 5,Novartis Pharma AG, 5,Plexxikon, 5,Pfizer, Inc., 5,Proximagen, 5,Regeneron, 5,Samumed, LLC, 5,Theralogix LLC, 5.

To cite this abstract in AMA style:

Tambiah J, Kennedy S, Ghandehari H, Swearingen C, Hochberg MC. Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/treatment-of-knee-osteoarthritis-with-sm04690-improved-womac-a1-pain-on-walking-results-from-a-52-week-randomized-double-blind-placebo-controlled-phase-2-study-of-a-nov/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-knee-osteoarthritis-with-sm04690-improved-womac-a1-pain-on-walking-results-from-a-52-week-randomized-double-blind-placebo-controlled-phase-2-study-of-a-nov/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology